苯甲酸钠作为早期精神病辅助治疗的有效性——CADENCE-BZ:一项随机对照试验的研究方案
该随机对照试验计划在澳大利亚昆士兰州招募160例早期精神病患者,随机接受12周苯甲酸钠1000 mg(500 mg每日两次)或安慰剂治疗,主要结局为阳性与阴性症状量表(PANSS)总分,同时评估功能、生活质量、体力活动、抑郁及血清氨基酸相关标志物等次要结局。
要点
- 早期精神病患者随机接受12周苯甲酸钠1000 mg(500 mg每日两次)或安慰剂治疗。
- 主要结局为PANSS总分,次要结局包括GAF、AQOL、APQ6、IPAQ、SIMPAQ、CGI、HDRS、OTI及PGI-I等。
- 探索性分析血清D-丙氨酸、L-丙氨酸、D-丝氨酸、L-丝氨酸、甘氨酸和谷氨酸从基线至终点的变化。
核心结论
- 该研究将检验一种安全且易获取的食品防腐剂是否有助于优化精神病患者的结局。
研究设计与样本
- 随机对照试验,计划在澳大利亚昆士兰州通过医院和社区精神卫生服务机构招募160例早期精神病患者。
- 患者随机接受12周苯甲酸钠1000 mg(500 mg每日两次)或安慰剂治疗。
- 患者每两周进行结局评估,每周进行持续知情同意能力、药物依从性和安全性评估。
- 试验注册于澳大利亚新西兰临床试验注册中心(ANZCTR),注册号ACRN12615000187549,注册日期2015年2月26日。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要结局指标为阳性与阴性症状量表(PANSS)总分。
- 次要结局包括全局功能评估(GAF)、生活质量评估量表(AQOL)、活动与参与问卷(APQ6)、国际体力活动问卷(IPAQ)、简易体力活动问卷(SIMPAQ)、体力活动问卷、临床总体印象(CGI)、汉密尔顿抑郁评定量表17项(HDRS)、阿片类治疗指数(OTI)及患者总体改善印象(PGI-I)。
- 第三级目标为研究血清D-丙氨酸、L-丙氨酸、D-丝氨酸、L-丝氨酸、甘氨酸和谷氨酸相关标志物从基线至终点的变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psychotic disorders affect up to 3% of the population and are often chronic and disabling. Innovation in the pharmacological treatment of psychosis has remained stagnant in recent decades. In order to improve outcomes for those with psychotic disorders, we present a protocol for the trial of a common food preservative, sodium benzoate, as an adjunctive treatment in early psychosis. METHODS: Persons experiencing early psychosis (n = 160) will be recruited through hospitals and community mental health services in Queensland, Australia. Patients will be randomized to receive either 12-week treatment with 1000 mg (500 mg twice daily (BD)) sodium benzoate or placebo. Patients will undergo fortnightly outcome assessments, in addition to weekly ongoing capacity to consent, drug compliance and safety assessments. The primary outcome measure is the Positive and Negative Syndrome Scale (PANSS) total score. Secondary outcomes are Global Assessment of Function (GAF), Assessment of Quality of Life Scale (AQOL), the Activity and Participation Questionnaire (APQ6), International Physical Activity Questionnaires (IPAQ), Simple Physical Activity Questionnaire (SIMPAQ), Physical Activity Questionnaire, Clinical Global Impression (CGI), Hamilton Depression rating Scale-17 items (HDRS), Opiate Treatment Index (OTI) and the Patients' Global Impression of Improvement (PGI-I). As a tertiary objective, changes from baseline to endpoint in to serum markers related to D-alanine, L-alanine, D-serine, L-serine, glycine and glutamate will be investigated. DISCUSSION: Consumers and clinicians are keen to help develop better treatments for those with psychosis. This study, part of the wider Cadence clinical trials platform will examine if a safe and accessible food preservative can help optimize outcomes in those with psychosis. TRIAL REGISTRATION: Australian New Zealand Clinical Trials registry (ANZCTR), ACTRN12615000187549 . Registered on 26 February 2015.
引用
- Ryan A, Baker A, Dark F, et al. The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28388932. doi:10.1186/s13063-017-1908-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。